Drugs Made In America Acquisition Corp. announces separate trading of shares and rights starting Feb 25

Drugs Made In America Acquisition Corp.

Effective Feb 25, 2025, holders of units (DMAAU) may separate into ordinary shares (DMAA) and rights (DMAAR).
Units not separated continue to trade on Nasdaq under DMAAU; separated shares and rights trade under DMAA and DMAAR.
Holders must contact VStock Transfer LLC via their broker to effect the separation; no fractional rights issued.
The company's IPO units were offered under registration statement effective Jan 7, 2025, with post-effective amendment Jan 27, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.